Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Journal of Cannabis Research|July 14, 2025
Patterns and factors among oncology fellows recommending medical cannabis to adults with cancerKian Tehranchi, Rushad Patell, Poorva Bindal, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 25, 2026
Multiple Chapters, One Career: Using Career Development Plans to Find Success and Satisfaction in Academic Oncology Across the Career SpectrumBrian M Russell, Richard D Hall, Kristin J Redmond, et al.
Translational Lung Cancer Research|June 15, 2026
Lung cancer with EGFR PACC mutations: a practical review of available treatment options and novel therapies on the horizonJulia M Berg, Hollis Viray, Jenna Green, et al.
Lung Cancer (Amsterdam, Netherlands)|May 20, 2020
Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infectionAna Pertejo-Fernandez, Biagio Ricciuti, Sarah P Hammond, et al.
JCO Oncology Practice|August 1, 2025
Fortifying the Workforce: A National Survey of Hematology/Oncology Fellowship Program Leaders Regarding Training Fellows for Community-Based CareersAnthony Iacoviello, Anika Patel, Shubham Agrawal, et al.
JCO Oncology Practice|February 8, 2024
Defining the Educational Needs for a Community-Based Hematology/Oncology Career: A National Needs AssessmentShubham Agrawal, Rushad Patell, Laura E Dodge, et al.
Lung Cancer (Amsterdam, Netherlands)|January 22, 2016
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutationSusan E Jorge, Sol Schulman, Jason A Freed, et al.
Cancers|March 28, 2024
A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical PracticeHollis Viray, Andrew J Piper-Vallillo, Page Widick, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2023
EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitorsWilliam Shaffer, Ikei S Kobayashi, Daniel Sentana-Lledo, et al.
JCO Oncology Practice|December 19, 2022
Training Hematologists/Oncologists for the Academic-Community Hybrid: Creating a Fellowship Framework for the FutureDaniel A Roberts, Jennifer Faig, Kelly Bodio-Downey, et al.
Pageof 7